PASW
PASW
Ping An Biomedical Co., Ltd.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2024 | $130.92K ▼ | $56.85M ▼ | $64.04M ▼ | $-7.19M ▼ |
| Q1-2024 | $969.62K | $79.55M | $85.11M | $-5.56M |
What's financially strong about this company?
Receivables and inventory have been reduced, which could mean better collections and less risk of unsold goods. Debt has also come down this quarter.
What are the financial risks or weaknesses?
The company has almost no cash, negative equity, and can't cover its short-term bills with its assets. If things don't improve quickly, it may struggle to keep operating.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|
5-Year Trend Analysis
A comprehensive look at Ping An Biomedical Co., Ltd.'s financial evolution and strategic trajectory over the past five years.
PASW has shown in the past that it can run a profitable operation and, in certain years, generate strong operating and free cash flow. The recent reduction in debt lessens some balance sheet pressure, and the lean asset structure without goodwill or large intangibles reduces the risk of sudden write-downs. Strategically, the pivot into biopharma via Future Biotechnology Group offers access to a potentially high-growth industry and advanced technologies, including AI-enabled manufacturing and specialized biotech processes, without the long lead time of building everything internally.
The company currently faces pronounced financial and strategic risks. Revenue and margins in the historical core business have weakened significantly, leading to recurring losses, negative equity, and tight liquidity. Cash flows are highly volatile, and the balance sheet offers a thin cushion against shocks. At the same time, PASW is entering one of the most capital-intensive and technically demanding industries with limited in-house experience and a heavy reliance on a single external partner whose pipeline, regulatory path, and commercial execution remain largely unproven in public data. These factors together heighten execution, financing, and industry-specific risks.
PASW’s outlook is best characterized as highly uncertain and transitional. The legacy business appears to be in decline, while the new biomedical direction is promising in concept but untested in practice. In the near to medium term, financial results are likely to remain volatile as the company manages weak historical operations, constrained liquidity, and the cash demands of its strategic pivot. Over the longer term, the trajectory will depend on whether Future Biotechnology Group can meet its ambitious targets, build a credible portfolio of products and services, and translate its technology into sustainable cash flows that can stabilize and reshape PASW’s overall financial profile.
About Ping An Biomedical Co., Ltd.
http://www.majestic-holdings-temp.flywhe...Ping An Biomedical Co., Ltd. engages in the provision of supply chain management services in the apparel industry delivering one-stop solutions to customers for a broad range of yarn products, textiles, and finished garments. It operates through the Yarns and Finished Garments segments. The company was founded by Yuk Yin Li and Sek Yan Ko in 2013 and is headquartered in Hong Kong.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2024 | $130.92K ▼ | $56.85M ▼ | $64.04M ▼ | $-7.19M ▼ |
| Q1-2024 | $969.62K | $79.55M | $85.11M | $-5.56M |
What's financially strong about this company?
Receivables and inventory have been reduced, which could mean better collections and less risk of unsold goods. Debt has also come down this quarter.
What are the financial risks or weaknesses?
The company has almost no cash, negative equity, and can't cover its short-term bills with its assets. If things don't improve quickly, it may struggle to keep operating.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|
5-Year Trend Analysis
A comprehensive look at Ping An Biomedical Co., Ltd.'s financial evolution and strategic trajectory over the past five years.
PASW has shown in the past that it can run a profitable operation and, in certain years, generate strong operating and free cash flow. The recent reduction in debt lessens some balance sheet pressure, and the lean asset structure without goodwill or large intangibles reduces the risk of sudden write-downs. Strategically, the pivot into biopharma via Future Biotechnology Group offers access to a potentially high-growth industry and advanced technologies, including AI-enabled manufacturing and specialized biotech processes, without the long lead time of building everything internally.
The company currently faces pronounced financial and strategic risks. Revenue and margins in the historical core business have weakened significantly, leading to recurring losses, negative equity, and tight liquidity. Cash flows are highly volatile, and the balance sheet offers a thin cushion against shocks. At the same time, PASW is entering one of the most capital-intensive and technically demanding industries with limited in-house experience and a heavy reliance on a single external partner whose pipeline, regulatory path, and commercial execution remain largely unproven in public data. These factors together heighten execution, financing, and industry-specific risks.
PASW’s outlook is best characterized as highly uncertain and transitional. The legacy business appears to be in decline, while the new biomedical direction is promising in concept but untested in practice. In the near to medium term, financial results are likely to remain volatile as the company manages weak historical operations, constrained liquidity, and the cash demands of its strategic pivot. Over the longer term, the trajectory will depend on whether Future Biotechnology Group can meet its ambitious targets, build a credible portfolio of products and services, and translate its technology into sustainable cash flows that can stabilize and reshape PASW’s overall financial profile.
CEO
Pijun Liu